OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting. Video Player is loading. This is a modal window. This video is either ...
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM Florent Malard Arthur Bobin Mohamad Mohty CorrespondenceOpen Access18 Dec 2024Blood Cancer Journal ...
This Review provides an update on the latest advances in the treatment of multiple myeloma. In particular, we focus on novel therapies including modulating protein homeostasis, kinases inhibitors, targeting accessory cells and cytokines, and immunomodulatory agents. A discussion of the challenges ...
Multiple Myeloma: What you need to know ByHealthClot Moderator May 28, 2023 0 Multiple Myeloma: What you need to know “Multiple myeloma symptoms” “Multiple myeloma treatment options” “Living with multiple myeloma” “Multiple myeloma diagnosis” “Multiple myeloma stages” “Multiple myeloma che...
Genes Highlight Who'll Benefit From Multiple Myeloma Therapy HealthDayDec. 4, 2024 Scientists Spot Gene That Could Help Cause Miscarriages HealthDayNov. 26, 2024 Human Cell Atlas Will Be 'Google Maps' for Health Research HealthDayNov. 20, 2024 ...
Multiple myeloma is the second most common hematologic malignancy. In Multiple myeloma a serum or urine monoclonal component is produced by bone marrow plasma cells. Great progresses have been made in the latest 10 years and survivals are nearly doubled. This improvement has been reached with novel...
Teclistamab is a T-cell-directed IgG4λ BsAb that recognizes B-Cell Maturation Antigen (BCMA) on target cells and CD3ε on T cells. As one of the promising BsAbs, teclistamab was granted orphan designations for the treatment of Multiple Myeloma (MM) in both the US and EU, the break...
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma Alfred L. Garfall CorrespondenceOpen Access03 Jan 2025Blood Cancer Journal Volume: 15, P: 1 TransTACs: novel heterobispecific antibodies for targeted protein degradation in cancer therapy ...
674 Citations Trial of Donanemab in Early Symptomatic Alzheimer Disease 463 Citations Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by Omicron and Delta Variants 446 Citations Diagnosis and Management of Multiple Myeloma 436 Citations Individuals With Persistent ...
By visiting this page often, patients and cancer survivors can stay up to date on the latest patient-focused research coming out of major oncology conferences.